Literature DB >> 23797340

Prostate cancer: stratifying intermediate-risk patients for radiotherapy.

Mark K Buyyounouski1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23797340     DOI： 10.1038/nrurol.2013.142

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.

Authors:  Yushen Qian; Felix Y Feng; Schuyler Halverson; Kevin Blas; Howard M Sandler; Daniel A Hamstra
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

3.  Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.

Authors:  Sean M Vance; Matthew H Stenmark; Kevin Blas; Schulyer Halverson; Daniel A Hamstra; Felix Y Feng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-04       Impact factor: 7.038

4.  The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.

Authors:  David J D'Ambrosio; Alexandra L Hanlon; Tahseen Al-Saleem; Steven J Feigenberg; Eric M Horwitz; Robert G Uzzo; Alan Pollack; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-22       Impact factor: 7.038

5.  Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.

Authors:  A R Kuykendal; L H Hendrix; R G Salloum; P A Godley; R C Chen
Journal:  Ann Oncol       Date:  2012-12-30       Impact factor: 32.976

6.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Isaac Pei; Zhigang Zhang; Yoshiya Yamada; Marisa Kollmeier; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-03-23       Impact factor: 20.096

7.  The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.

Authors:  Radka Stoyanova; Niraj H Pahlajani; Brian L Egleston; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

8.  Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

Authors:  Katherine O Castle; Karen E Hoffman; Lawrence B Levy; Andrew K Lee; Seungtaek Choi; Quynh N Nguyen; Steven J Frank; Thomas J Pugh; Sean E McGuire; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-24       Impact factor: 7.038
  8 in total
  1 in total

1.  Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.

Authors:  Ho Won Kang; Hae Do Jung; Joo Yong Lee; Jong Kyou Kwon; Seong Uk Jeh; Kang Su Cho; Won Sik Ham; Young Deuk Choi
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.